Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Lineage Cell Therapeutics Inc (LCTX)

Lineage Cell Therapeutics Inc (LCTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Lineage Cell Therapeutics Inc 2173 SALK AVENUE SUITE 200 CARLSBAD CA 92008 USA

https://lineagecell.com Employees: 75 P: 442-287-8990

Description:

Lineage Cell Therapeutics Inc. is a clinical-stage biotechnology company. It focuses on developing and commercializing therapies for the treatment of degenerative diseases primarily in the United States and internationally. The company's lead product candidates include OpRegen, OPC1 and VAC2 which are in clinical stage. Lineage Cell Therapeutics Inc., formerly known as BioTime Inc., is based in Carlsbad, California.

Key Statistics

Overview:

Market Capitalization, $K 118,584
Enterprise Value, $K 83,144
Shares Outstanding, K 220,416
Annual Sales, $ 8,950 K
Annual Net Income, $ -21,490 K
Last Quarter Sales, $ 3,780 K
Last Quarter Net Income, $ -3,030 K
EBIT, $ -22,730 K
EBITDA, $ -21,950 K
60-Month Beta 1.16
% of Insider Shareholders 23.60%
% of Institutional Shareholders 62.47%
Float, K 168,398
% Float 76.40%
Short Volume Ratio 0.38

Growth:

1-Year Return -50.64%
3-Year Return -78.04%
5-Year Return -35.23%
5-Year Revenue Growth 79.36%
5-Year Earnings Growth 61.29%
5-Year Dividend Growth -100.00%

Per-Share Information:

Most Recent Earnings -0.02 on 11/14/24
Next Earnings Date N/A
Earnings Per Share ttm -0.12
EPS Growth vs. Prev Qtr 33.33%
EPS Growth vs. Prev Year 50.00%
Annual Dividend Yield 0.00%
Most Recent Dividend 0.080 on 12/15/03
Dividend Payout Ratio 0.00%

LCTX Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -30.39%
Return-on-Assets % -19.67%
Profit Margin % -240.11%
Debt/Equity 0.00
Price/Sales 13.52
Price/Cash Flow N/A
Price/Book 1.60
Book Value/Share 0.34
Interest Coverage -15.28

LCTX Dividends

Date Value
12/15/03 $0.0800
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar